What does this research mean for the field?

Among hospitalized patients with insulin-requiring diabetes, the use of automated insulin delivery (AID) is associated with higher levels of shared decision-making compared to continuous glucose monitoring alone or usual care. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to assess the levels of shared decision-making (SDM) experienced by hospitalized patients with diabetes using different technology exposures.

June 7, 2026

2799-LB: Does Diabetes Technology Influence Person-Centered Care in the Hospital?

Key Points

This research aims to assess the levels of shared decision-making (SDM) experienced by hospitalized patients with diabetes using different technology exposures.
Participants with insulin-requiring diabetes (NCT05590143) completed the Shared Decision-Making Questionnaire 9 (SDM-Q-9).
Three groups: nurse-driven automated insulin delivery (AID), continuous glucose monitoring (CGM) alone, and usual care (no technology).
A total of 99 participants with varying ages and demographics were assessed for their experience of SDM.
SDM-Q-9 scores were highest in the AID group (76.7), followed by CGM-only (61.1) and no-technology (55.6).
Participants reporting SDM ranged from 80.5% in the AID group to 58.6% in the no-technology group.
The study indicates a significant benefit of AID in facilitating person-centered care.

Abstract

Introduction and Objective: Shared decision-making (SDM) is a core component of person-centered care, yet its use in hospitalized people with diabetes is not known. As diabetes technology expands, new opportunities may exist to involve patients in their care. We evaluated the degree of SDM experienced by hospitalized patients across three levels of diabetes technology exposure. Methods: Participants with insulin-requiring diabetes enrolled in a clinical trial (NCT05590143) and an observational study with the same eligibility criteria completed the Shared Decision-Making Questionnaire 9 (SDM-Q-9) survey. Three levels of exposure to technology were assessed: nurse-driven automated insulin delivery (AID) (n=36), CGM alone (n=34), and usual care without diabetes technology (n=29). Results: Participants (mean age 55 years, 39% female, 61% Black, and 33% White) overall SDM-Q-9 scores (scale: 0-100 for low-high SDM), reported as median (IQR), were 76.7 (45.6-87.2), 61.1 (42.2-80.0), and 55.6 (24.4-73.3) for the AID, CGM-only, and no-technology groups, respectively. The percentage of participants reporting SDM (completely, strongly, or somewhat agree) was 80.5%, 76.5%, and 58.6% in the AID, CGM-only, and no-technology groups, respectively. Conclusion: In this cohort of insulin-requiring hospitalized patients, SDM was highest among those using AID, highlighting the potential of AID to support more person-centered care in the inpatient setting. Disclosure J.M. Feeley: Research Support; Current; Dexcom, Inc. R. Parab: None. S. Usman: None. L. Chadalawada: None. S. Hur: Research Support; Current; Dexcom, Inc. N. Gonzalez: None. M. Weber: None. G.M. Davis: Research Support; Current; Insulet Corporation, Sequel Med Tech. M.S. Hughes: Consultant; Current; Dexcom, Inc., Sanofi, Sequel Med Tech, LLC. R. Lal: Consultant; Current; Abbott Diabetes, Adaptyx Biosciences. Consultant; Ended; Biolinq, Capillary Biomedical, Deep Valley Labs. Consultant; Current; Gluroo, Portal Diabetes, Tidepool. Advisory Panel; Ended; ProventionBio, Lilly, Sanofi, Rezolute. S. Brown: Research Support; Current; Insulet Corporation, Tandem Diabetes Care, Inc., Dexcom, Inc. Research Support; Ended; Roche Diabetes Care, Tolerion, Inc. F.J. Pasquel: Research Support; Current; Dexcom, Inc., Insulet Corporation, Ideal Medical Technologies. Research Support; Ended; Novo Nordisk, Tandem Diabetes Care, Inc. Consultant; Ended; Insulet Corporation. Funding Supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (UL1TR002378 and TL1TR002382), the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK138366), Dexcom, and Insulet.

Mark Helpful

Bookmark

Relay